BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Contract Services

AGC Biologics Sets New Benchmark in Japan With 5,000 L Single-Use Bioreactors at Yokohama CDMO Site

New CDMO site introducing the most advanced and large-scale single-use bioreactors in Japan AGC announced a strategic decision about the large-scale singl...

April 08, 2025 | News

TCI Biotech Elevates CDMO+ Services with US-Based Glass Bottling for Liquid Supplements

TCI Biotech (TCI Co., Ltd.), a CDMO+ organization specializing in health and wellness products, is spotlighting its comprehensive US-based glass bottling s...

April 03, 2025 | News

Langhua Pharmaceutical Receives FDA EIR Following Successful cGMP Inspection for the Fourth Time

Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings ("Viva Biotech"), underwent a cGMP...

March 31, 2025 | News

Porton Advanced and Eureka Therapeutics Partner to Advance Next-Gen T-Cell Therapies

Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleas...

March 20, 2025 | News

Celonic Integrates Merck’s Breez™ Micro-Bioreactor to Advance mAb Development

Celonic Group, a Swiss-Based Quality contract development and manufacturing organization (CDMO), has announced that it is integrating Merck’s Breez&t...

March 13, 2025 | News

Vetter to Double Cool Storage Capacity by 2028 with €150M Investment

Cool storage volume to be doubled by 2028 Third expansion stage of Vetter’s Center for Visual Inspection and Logistics State-of-the art, fully au...

March 11, 2025 | News

WuXi Biologics Introduces EffiX™ a High-Yield E. coli Expression Platform for Recombinant Proteins and Plasmid DNA Production

EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. ...

March 04, 2025 | News

WuXi XDC Expands Partnership with LigaChem to Accelerate Next-Gen ADC Development

WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organiz...

February 26, 2025 | News

LabConnect and ACL Specialised Trials Partner to Strengthen Clinical Trial Support in Australia and APAC

LabConnect and Australian Clinical Labs' (ACL) Specialised Trials have forged a strategic partnership to expand support of clinical trials in Aus...

February 25, 2025 | News

Chime Biologics and Mabgeek Advance MG-K10 to U.S. Phase III Trials for Atopic Dermatitis and Asthma

Chime Biologics, a leading global CDMO that enables its partners' success in biologics, announced its continued collaboration with Mabgeek ...

February 24, 2025 | News

Eleva and 3PBIOVIAN Forge Strategic Alliance to Advance Clinical-Grade Biologics Production

3PBIOVIAN provides production capacity for clinical-grade material for current and future development programs including Eleva’s proprietary Factor...

February 05, 2025 | News

Cognizant and Medidata Expand AI-Driven Partnership to Advance Clinical Trials

The organizations plan to support clients through expanded partnership and offer broader access to Medidata's AI-powered technologies to accelerate clinica...

January 31, 2025 | News

Samsung Biologics Eyes Growth in 2025 with New Plant, ADC Services, and Sustainability Investments

Recorded Q4'24 consolidated revenue of KRW 1.26 trillion Recorded FY'24 consolidated revenue of KRW 4.55 trillion Poised for further growth w...

January 23, 2025 | News

Lyndra Partners with Thermo Fisher to Drive Phase 3 Trials and Commercial Manufacturing of Long-Acting Oral Therapies

Leveraging its Accelerator™ Drug Development, 360° CDMO and CMO solutions, Thermo Fisher will provide clinical research services for Lyndra...

January 16, 2025 | News

Stay Connected